OncoCyte
About: OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
Employees: 46
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
15% more funds holding
Funds holding: 20 [Q3] → 23 (+3) [Q4]
8.55% less ownership
Funds ownership: 53.6% [Q3] → 45.05% (-8.55%) [Q4]
12% less capital invested
Capital invested by funds: $20.4M [Q3] → $18.1M (-$2.37M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for OCX.
Financial journalist opinion
Based on 4 articles about OCX published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah.
Neutral
MCAP MediaWire
1 week ago
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
IRVINE, Calif., Feb. 11, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah.
Neutral
MCAP MediaWire
1 week ago
Oncocyte Prices $29.1 Million Equity Offering
IRVINE, Calif., Feb. 10, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE Offering”).
Neutral
GlobeNewsWire
1 week ago
Oncocyte Prices $29.1 Million Equity Offering
Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE Offering”).
Neutral
GlobeNewsWire
1 month ago
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer
Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer.
Neutral
MCAP MediaWire
1 month ago
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer
Irvine, Calif., Jan. 8, 2025 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer.
Neutral
GlobeNewsWire
1 month ago
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney
Medicare coverage expanded following study showing that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA) MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-Code Up to 20% of patients will have detectable DSA within the first five years post kidney transplant, representing greater than 10,000 patients per year in the US.1 From time of onset of dnDSA, 24% of patients will lose their allograft within 3 years compared to the 96% five-year allograft survival for patients without DSA.1 Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection. IRVINE, Calif.
Neutral
MCAP MediaWire
1 month ago
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney
Irvine, Calif., January 6, 2025 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a leader in diagnostic technology, today announced a significant milestone in the advancement of patient care for kidney transplant patients.
Neutral
MCAP MediaWire
2 months ago
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
January 13-16, 2025, San Francisco, CA IRVINE, Calif., December 9, 2024 – PRISM MediaWire – Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P.
Neutral
GlobeNewsWire
2 months ago
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P.
Charts implemented using Lightweight Charts™